Accéder au contenu
Merck

Nucleotide biosynthesis links glutathione metabolism to ferroptosis sensitivity.

Life science alliance (2022-01-26)
Amy Tarangelo, Jason Rodencal, Joon Tae Kim, Leslie Magtanong, Jonathan Z Long, Scott J Dixon
RÉSUMÉ

Nucleotide synthesis is a metabolically demanding process essential for DNA replication and other processes in the cell. Several anticancer drugs that inhibit nucleotide metabolism induce apoptosis. How inhibition of nucleotide metabolism impacts non-apoptotic cell death is less clear. Here, we report that inhibition of nucleotide metabolism by the p53 pathway is sufficient to suppress the non-apoptotic cell death process of ferroptosis. Mechanistically, stabilization of wild-type p53 and induction of the p53 target gene CDKN1A (p21) leads to decreased expression of the ribonucleotide reductase (RNR) subunits RRM1 and RRM2 RNR is the rate-limiting enzyme of de novo nucleotide synthesis that reduces ribonucleotides to deoxyribonucleotides in a glutathione-dependent manner. Direct inhibition of RNR results in conservation of intracellular glutathione, limiting the accumulation of toxic lipid peroxides and preventing the onset of ferroptosis in response to cystine deprivation. These results support a mechanism linking p53-dependent regulation of nucleotide metabolism to non-apoptotic cell death.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hydroxyurée, 98%, powder
Sigma-Aldrich
Ferrostatin-1, ≥95% (HPLC)
Sigma-Aldrich
L-Buthionine-sulfoximine, ≥97% (TLC)
Sigma-Aldrich
Mycophenolic acid, ≥98%